Cost-effectiveness of risk-stratified hepatocellular carcinoma screening using the age-male-albumin-bilirubin-platelets score-based stepwise enrichment approach in patients with cirrhosis

doi:10.3748/wjg.121840

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 46

This Article

(7)

(8)

(0)

(5)

(84)

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 14, 2026; 32(46): 121840
Published online Dec 14, 2026. doi: 10.3748/wjg.121840

Full Size Figure Download Figure

Figure 3 Cost-effectiveness acceptability curves for all strategies under varying intervals of periodic re-stratification testing. Dashed curves indicate screening strategies that never have the highest probability of being cost-effective within the willingness-to-pay threshold of three-times per-capita gross domestic product (only a subset is indicated in the legend), while solid curves represent screening strategies that may have the highest probability of being cost-effective within this threshold. Costs and quality-adjusted life-years are expressed as the value in 2024. WTP: Willingness-to-pay; GDP: Gross domestic product; US: Ultrasound; AFP: Alpha fetoprotein; QALY: Quality-adjusted life-year; Gd-MRI: Gadoxetic-enhanced magnetic resonance imaging; CE-MRI: Contrast-enhanced magnetic resonance imaging.

Citation: Zhang YB, Li YX, Zhang WD, Hou XB, Li R, Xia RY, Shen MW, Zou ZR, Zhuang GH. Cost-effectiveness of risk-stratified hepatocellular carcinoma screening using the age-male-albumin-bilirubin-platelets score-based stepwise enrichment approach in patients with cirrhosis. World J Gastroenterol 2026; 32(46): 121840
URL: https://www.wjgnet.com/1007-9327/full/v32/i46/121840.htm
DOI: https://dx.doi.org/10.3748/wjg.121840

Zhang YB, Li YX, Zhang WD, Hou XB, Li R, Xia RY, Shen MW, Zou ZR, Zhuang GH. Cost-effectiveness of risk-stratified hepatocellular carcinoma screening using the age-male-albumin-bilirubin-platelets score-based stepwise enrichment approach in patients with cirrhosis. World J Gastroenterol 2026; 32(46): 121840 [DOI: 10.3748/wjg.121840]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.